Free tool
FAERS Monitor: Byqlovi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 218158 or its brand name (Byqlovi, Clobetasol Propionate). Reports on generic versions are filed under their own applications.
Reports
10,595
Serious
4,972
47% of reports
Hospitalization
2,058
Death reported
439
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,087
- pruritus983
- off label use682
- rash676
- product use in unapproved indication553
- psoriasis550
- fatigue531
- headache501
- diarrhoea448
- nausea441
- dry skin423
- arthralgia421
- pain404
- skin exfoliation399
- erythema341
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 17 |
| 2005 | 20 |
| 2006 | 58 |
| 2007 | 92 |
| 2008 | 95 |
| 2009 | 125 |
| 2010 | 135 |
| 2011 | 215 |
| 2012 | 318 |
| 2013 | 162 |
| 2014 | 185 |
| 2015 | 346 |
| 2016 | 403 |
| 2017 | 536 |
| 2018 | 459 |
| 2019 | 471 |
| 2020 | 558 |
| 2021 | 604 |
| 2022 | 920 |
| 2023 | 1,216 |
| 2024 | 1,152 |
| 2025 | 1,320 |
| 2026 | 1,188 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,564 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| skin exfoliationSignal | 399 | 9.4 | 8.6 | 2,996 |
| psoriasisSignal | 550 | 8.4 | 7.7 | 3,580 |
| dry skinSignal | 423 | 6.3 | 5.7 | 1,890 |
| pruritusSignal | 983 | 5.1 | 4.8 | 3,276 |
| product use in unapproved indicationSignal | 553 | 4.4 | 4.1 | 1,483 |
| erythemaSignal | 341 | 3.3 | 3.0 | 548 |
| rashSignal | 676 | 3.1 | 2.9 | 967 |
| arthralgiaSignal | 421 | 2.0 | 1.8 | 217 |
| drug ineffective | 1,087 | 1.6 | 1.5 | 287 |
| headache | 501 | 1.6 | 1.5 | 111 |
| off label use | 682 | 1.5 | 1.4 | 137 |
| diarrhoea | 448 | 1.4 | 1.3 | 48 |
| fatigue | 531 | 1.4 | 1.2 | 51 |
| pain | 404 | 1.3 | 1.2 | 29 |
| nausea | 441 | 1.1 | 1.0 | 5 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.